Development of a robust T cell assay to retrospectively diagnose SARS-CoV-2 infection and T cell cytokine release assay as diagnostic and monitoring assay in Long COVID patients

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
  • Total publications:10 publications

Grant number: COV-LT2-0004

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2023
  • Known Financial Commitments (USD)

    $521,757.6
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
  • Principal Investigator

    N/A

  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Cambridge
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The current COVID-19 pandemic caused by coronavirus (SARS-CoV-2), has already infected close to 150 million people with over 3 million deaths worldwide. Unfortunately, a significant proportion of people continue to experience distressing and life altering symptoms several months after the initial illness. People with persistent symptoms are currently classified as having Long COVID. Diagnosis of Long COVID is hampered especially in the group of non-hospitalised patients as the majority had asymptomatic to mild infection hence less likely to have generated antibodies against coronavirus and antibody tests miss a significant proportion of patients (~30%). We therefore propose to develop a COVID diagnostic assay that is based on detecting the aspect of the body s immune response (T cell response) that is triggered in this case in response to coronavirus and is most likely to be detected several months to years following infection. The diagnostic assay will be used in clinical setting. This research proposal was birthed in consultation with patients suffering from Long COVID since the initial wave. We set up a Long COVID clinic for non-hospitalised patients in May 2020 at Addenbrooke s, to provide better clinical care and enroll patients into the Cambridge COVID NIHR BioResource. The enrolled patients had bloods taken and we have preliminary results that show our study s feasibility and we want to scale this to an assay that will be able to process high volumes of samples with quick turnaround of results. We will continue to enroll patients and follow them up every 3 months for up to 18 months. We will disseminate our research findings to the public and patients via bulletins to GPs, patient information leaflets generated by the Addenbrooke s media and communications department and to the scientific and medical community via local medical grand rounds, publications in high impact scientific journals and departmental meetings.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly.

Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity.

Reduced Incidence of Long Coronavirus Disease Referrals to the Cambridge University Teaching Hospital Long Coronavirus Disease Clinic.

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18  influenza seasons.

Demographic, behavioural and occupational risk factors associated with SARS-CoV-2 infection in UK healthcare workers: a retrospective observational study.

Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study.

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses.

Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID.

Investigation of healthcare-associated SARS-CoV-2 infection: Learning outcomes from an investigative process in the initial phase of the pandemic.